WINT Stock Price, Windtree Therapeutics, . Quote, Chart

Market Summary

USD5.01+0.68

Market Closed

15.70%

WINT Stock Price

View Fullscreen

WINT RSI Chart

WINT Valuation

Market Cap

46.0M

Price/Earnings (Trailing)

-2.27

Price/Sales (Trailing)

242.57

EV/EBITDA

-2.06

Price/Free Cashflow

-3.42

WINT Price/Sales (Trailing)

WINT Profitability

EBT Margin

-10247.98%

Return on Equity

-598.64%

Return on Assets

-62.64%

Free Cashflow Yield

-29.24%

WINT Fundamentals

WINT Revenue

Revenue (TTM)

198.0K

WINT Earnings

Earnings (TTM)

-20.3M

Earnings Growth (Yr)

46.73%

Earnings Growth (Qtr)

-16.68%

Breaking Down WINT Revenue

Last 7 days

-4.2%

Last 30 days

-26.7%

Last 90 days

-30.4%

Trailing 12 Months

-81.8%

How does WINT drawdown profile look like?

WINT Financial Health

Current Ratio

1.34

Debt/Equity

3.69

Debt/Cashflow

-1.07

WINT Investor Care

Shares Dilution (1Y)

910.24%

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2019	1.4M	993.0K	595.5K	198.0K
2018	1.5M	1.4M	1.6M	1.8M
2017	2.2M	2.0M	1.7M	1.5M
2016	871.0K	902.0K	1.8M	2.0M
2015	2.4M	1.9M	1.4M	987.0K
2014	999.8K	1.6M	2.2M	2.8M
2013	267.0K	449.0K	509.0K	388.0K
2012	0	0	0	396.0K
2011	0	0	0	582.0K

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Windtree Therapeutics, Inc.

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Sep 27, 2023	fraser craig	bought	2,549	1.0199	2,500	president and ceo
Sep 26, 2023	fraser craig	bought	2,250	0.9	2,500	president and ceo
Aug 23, 2023	simonson steven	acquired	-	-	15,867	svp, chief medical officer
Aug 23, 2023	curtis eric	acquired	-	-	14,667	svp & coo
Aug 23, 2023	williams leslie j.	acquired	-	-	2,033	-
Aug 23, 2023	strobeck mark	acquired	-	-	2,300	-
Aug 23, 2023	geffken daniel e.	acquired	-	-	2,033	-
Aug 23, 2023	fraser craig	acquired	-	-	45,867	president and ceo
Aug 23, 2023	scott robert a	acquired	-	-	2,033	-
Apr 26, 2023	fraser craig	bought	2,649	1.77	1,497	president and ceo

Which funds bought or sold WINT recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 01, 2024	CONCOURSE FINANCIAL GROUP SECURITIES, INC.	sold off	-	-	-	-%
May 01, 2024	CONCOURSE FINANCIAL GROUP SECURITIES, INC.	sold off	-	-	-	-%
Mar 11, 2024	VANGUARD GROUP INC	unchanged	-	-9,561	29,939	-%
Feb 26, 2024	Virtu Financial LLC	new	-	28,000	28,000	-%
Feb 14, 2024	CITADEL ADVISORS LLC	new	-	27,414	27,414	-%
Feb 14, 2024	Alyeska Investment Group, L.P.	unchanged	-	-31,345	98,156	-%
Feb 13, 2024	GEODE CAPITAL MANAGEMENT, LLC	unchanged	-	-3,486	10,207	-%
Feb 13, 2024	Tower Research Capital LLC (TRC)	sold off	-100	-9,175	-	-%
Feb 13, 2024	MORGAN STANLEY	reduced	-33.33	-2.00	1.00	-%
Feb 12, 2024	OSAIC HOLDINGS, INC.	unchanged	-	-	1.00	-%

Are Funds Buying or Selling WINT?

Are funds buying WINT calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own WINT

No. of Funds

Unveiling Windtree Therapeutics, Inc.'s Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2024	lincoln park capital fund, llc	181%	339,167	SC 13G/A
Feb 13, 2024	lind global fund ii lp	5.3%	290,102	SC 13G/A
Feb 01, 2024	flynn james e	7.59%	608,272	SC 13G
Nov 13, 2023	duvvuri krishna	6.35%	326,900	SC 13G
May 17, 2023	huang james	1.3%	68,984	SC 13D/A
Apr 28, 2023	lind global fund ii lp	9.9%	475,102	SC 13G
Apr 24, 2023	lincoln park capital fund, llc	9.99%	459,042	SC 13G
Apr 19, 2023	huang james	-	0	SC 13D/A
Feb 23, 2023	huang james	7.9%	3,449,161	SC 13D/A
Feb 09, 2023	huang james	7.8%	3,487,586	SC 13D/A

Recent SEC filings of Windtree Therapeutics, Inc.

View All Filings

Date Filed	Form Type	Document
Apr 23, 2024	8-K	Current Report
Apr 19, 2024	EFFECT	EFFECT
Apr 19, 2024	8-K	Current Report
Apr 17, 2024	8-K	Current Report
Apr 17, 2024	S-3/A	S-3/A
Apr 16, 2024	10-K	Annual Report
Apr 10, 2024	8-K	Current Report
Apr 08, 2024	8-K	Current Report
Apr 02, 2024	NT 10-K	NT 10-K
Mar 12, 2024	DEF 14A	DEF 14A

Peers (Alternatives to Windtree Therapeutics, Inc.)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	47.9B	6.8B	23.52%	-6.94%	-8.03	7	-64.45%	-224.75%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	19.3B	2.0B	0.99%	-25.83%	-58.02	9.62	75.20%	68.82%
BMRN	15.7B	2.5B	-4.94%	-13.58%	76.24	6.34	13.74%	186.89%
INCY	12.1B	3.8B	-2.80%	-18.78%	16.19	3.2	8.58%	129.81%
MID-CAP
APLS	5.7B	396.6M	-16.72%	-43.78%	-10.82	14.42	425.83%	18.94%
BBIO	5.2B	107.9M	-4.79%	106.15%	-9.53	48.09	54.84%	-28.31%
AXSM	3.5B	270.6M	1.74%	5.10%	-14.81	13.09	440.80%	-27.84%
ARWR	3.0B	240.7M	-7.74%	-39.00%	-10.2	12.18	-1.03%	-92.09%
ACAD	2.8B	726.4M	-7.55%	-20.97%	-45.79	3.86	40.45%	71.62%
SMALL-CAP
CPRX	1.7B	398.2M	-4.91%	-11.58%	24.31	4.36	85.90%	-14.05%
NVAX	687.2M	983.7M	8.15%	-35.14%	-1.26	0.7	-50.36%	17.16%
CRBP	408.0M	881.7K	0.99%	345.87%	-9.15	466.16	-77.61%	-5.33%
INO	282.8M	4.9M	-1.94%	21.49%	-2.09	58.11	-54.97%	51.71%
IBIO	6.9M	2.1M	-32.65%	86.79%	-0.25	2.14	-13.45%	66.37%

Windtree Therapeutics, Inc. News

Latest updates

Windtree Therapeutics, Inc. Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4	2018Q3	2018Q2	2018Q1	2017Q4	2017Q3	2017Q2	2017Q2	2017Q1	2016Q4	2016Q3	2016Q2	2016Q1	2015Q4	2015Q3	2015Q2	2015Q1
Revenue	-	-	-	0.00	0.00	0.00	0.00	1.00	0.00	0.00	0.00	1.00	1.00	0.00	1.00	1.00	0.00	0.00	1.00	0.00	0.00	1.00
Operating Expenses	-36.6%	5.00	7.00	7.00	7.00	5.00	4.00	4.00	5.00	-	-	-	-	-	-	-	-	-	-	-	-	-
S&GA Expenses	-28.9%	2.00	3.00	3.00	3.00	3.00	2.00	1.00	2.00	-	-	-	-	-	-	-	-	-	-	-	-	-
R&D Expenses	-43.6%	2.00	4.00	3.00	3.00	2.00	2.00	3.00	3.00	-	-	-	-	-	-	-	-	-	-	-	-	-
Interest Expenses	30.5%	0.00	0.00	0.00	0.00	1.00	0.00	0.00	0.00	-	-	-	-	-	-	-	-	-	-	-	-	-
Net Income	-3.5%	-7.37	-7.13	-6.44	-6.54	-9.04	-3.93	-3.05	-4.51	-	-	-	-	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Assets	-10.1%	32.00	36.00	41.00	35.00	38.00	48.00	52.00	67.00	75.00	85.00	91.00	136	113	119	128	113	119	101	105	112	119
Current Assets	-39.6%	5.00	9.00	13.00	5.00	7.00	10.00	13.00	16.00	23.00	26.00	32.00	39.00	18.00	24.00	34.00	18.00	24.00	5.00	10.00	16.00	26.00
Cash Equivalents	-41.6%	4.00	7.00	11.00	4.00	6.00	8.00	11.00	16.00	22.00	25.00	30.00	38.00	17.00	22.00	32.00	17.00	23.00	4.00	6.00	2.00	11.00
Net PPE	-10.7%	0.00	0.00	0.00	0.00	0.00	0.00	0.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00
Goodwill	-	-	-	-	3.00	3.00	4.00	4.00	16.00	16.00	16.00	16.00	16.00	16.00	16.00	16.00	16.00	16.00	16.00	16.00	16.00	16.00
Liabilities	1.5%	29.00	29.00	29.00	28.00	28.00	31.00	33.00	32.00	33.00	35.00	34.00	44.00	43.00	43.00	45.00	43.00	44.00	48.00	47.00	49.00	51.00
Current Liabilities	8.1%	4.00	4.00	4.00	3.00	2.00	4.00	5.00	5.00	5.00	5.00	5.00	7.00	6.00	6.00	12.00	7.00	8.00	16.00	16.00	17.00	21.00
Short Term Borrowings	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	8.00	8.00	7.00	8.00
Shareholder's Equity	-54.7%	3.00	7.00	12.00	7.00	10.00	17.00	19.00	35.00	42.00	50.00	57.00	91.00	70.00	76.00	83.00	70.00	75.00	53.00	58.00	63.00	68.00
Retained Earnings	-0.6%	-844	-839	-835	-828	-824	-814	-810	-793	-785	-772	-764	-726	-717	-710	-701	-691	-685	-677	-670	-664	-657
Additional Paid-In Capital	0.1%	851	850	850	839	838	835	833	831	830	825	824	821	790	789	788	765	763	734	732	730	729
Shares Outstanding	16.5%	6.00	5.00	5.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	0.00	0.00	0.00	-	-	-	-	-	-	-	-
Float	-	-	-	6.00	-	-	-	9.00	-	-	-	44.00	-	-	-	67.00	-	-	-	31.00	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Cashflow From Operations	7.4%	-3,567	-3,854	-3,497	-2,519	-3,380	-4,099	-5,258	-6,715	-4,932	-5,281	-7,403	-6,048	-4,539	-8,256	-7,038	-5,482	-5,459	-3,824	-6,621	-8,759	-6,191
Cashflow From Investing	100.0%	-	-15.00	-	-	-	-	200	-3.00	-173	-103	-3.00	-	-264	-15.00	-	-	-62.00	2,597	10,837	425	-13,736
Cashflow From Financing	323.6%	521	-233	10,716	591	1,116	1,157	895	-89.00	2,912	-40.00	-1,119	27,608	48.00	-1,137	21,246	-199	22,739	-346	-27.00	-598	30,417

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

WINT Income Statement

2023-12-31

Consolidated Statements of Operations - USD ($) shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Research and development	$ 8,341	$ 11,099
General and administrative	9,198	10,790
Loss on impairment of goodwill	3,058	12,624
Loss on impairment of intangible assets	0	6,820
Total operating expenses	20,597	41,333
Operating loss	(20,597)	(41,333)
Other income (expense):
Interest income	325	109
Interest expense	(50)	(53)
Other income, net	31	702
Total other income, net	306	758
Loss before income taxes	(20,291)	(40,575)
Deferred income tax benefit	0	1,367
Net loss	$ (20,291)	$ (39,208)
Net loss per common share
Basic and diluted (in dollars per share)	$ (5.24)	$ (62.23)
Weighted average number of common shares outstanding
Basic and diluted (in shares)	3,876	630

WINT Balance Sheet

2023-12-31

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Current Assets:
Cash and cash equivalents	$ 4,319	$ 6,172
Prepaid expenses and other current assets	1,060	1,205
Total current assets	5,379	7,377
Property and equipment, net	183	262
Restricted cash	150	154
Operating lease right-of-use assets	1,444	1,853
Intangible assets	25,250	25,250
Goodwill	0	3,058
Total assets	32,406	37,954
Current Liabilities:
Accounts payable	809	249
Accrued expenses	1,618	1,552
Operating lease liabilities - current portion	436	404
Loans payable - current portion	233	252
Other current liabilities	900	0
Total current liabilities	3,996	2,457
Operating lease liabilities - non-current portion	1,161	1,624
Restructured debt liability - contingent milestone payments	15,000	15,000
Other liabilities	3,800	3,800
Deferred tax liabilities	5,058	5,061
Total liabilities	29,015	27,942
Stockholders’ Equity:
Preferred stock, $0.001 par value; 5,000,000 and 4,960,000 shares authorized; 0 shares issued and outstanding at 2023 and 2022, respectively	0	0
Common stock, $0.001 par value; 120,000,000 shares authorized; 5,996,587 and 772,203 shares issued at 2023 and 2022, respectively; 5,996,586 and 772,202 shares outstanding at 2023 and 2022, respectively	6	0
Additional paid-in capital	851,262	837,598
Accumulated deficit	(844,823)	(824,532)
Treasury stock (at cost); 1 share	(3,054)	(3,054)
Total stockholders’ equity	3,391	10,012
Total liabilities, mezzanine equity & stockholders’ equity	32,406	37,954
Series A Preferred Stock [Member]
Current Liabilities:
Series A redeemable preferred stock, $0.001 par value; 0 and 40,000 shares authorized; 0 and 38,610.119 shares issued and outstanding at 2023 and 2022, respectively	$ 0	$ 0

About Windtree Therapeutics, Inc.

Windtree Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of acute cardiovascular diseases. The company's lead development programs include istaroxime, which is in Phase 2b clinical trial for the treatment of acute decompensated heart failure, as well as in Phase 2a clinical trial for the treatment of early cardiogenic shock; AEROSURF, an aerosolized KL4 surfactant, which is in Phase 2b clinical trial to treat respiratory distress syndrome in premature infants; Surfaxin, a lyophilized KL4 surfactant, which is in Phase 2a clinical trial for the treatment of lung injury resulting from COVID-19; Rostafuroxin that is in Phase 2b clinical trial for the treatment of genetically associated hypertension; and oral and intravenous SERCA2a activator, which is in preclinical trial for the treatment of chronic and acute heart failure. Windtree Therapeutics, Inc. has a collaboration with Universita degli Studi di Milano-Bicocca for the discovery and development of new SERCA2a compounds for the treatment of chronic and acute human heart failure; a strategic alliance with Laboratorios del Dr. Esteve, S.A. for the development, marketing, and sales of a portfolio of potential KL4 surfactant products; and collaboration with Battelle Memorial Institute for development of its ADS for use in its phase III program. The company was formerly known as Discovery Laboratories, Inc. and changed its name to Windtree Therapeutics, Inc. in April 2016. The company was founded in 1992 and is headquartered in Warrington, Pennsylvania.

CEO	Mr. Craig E. Fraser
WEBSITE	https://windtreetx.com
INDUSTRY	Biotechnology
EMPLOYEES	20

Windtree Therapeutics, Inc. Frequently Asked Questions

What is the ticker symbol for Windtree Therapeutics, Inc.? What does WINT stand for in stocks?

WINT is the stock ticker symbol of Windtree Therapeutics, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Windtree Therapeutics, Inc. (WINT)?

As of Fri May 03 2024, market cap of Windtree Therapeutics, Inc. is 46.01 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of WINT stock?

You can check WINT's fair value in chart for subscribers.

What is the fair value of WINT stock?

You can check WINT's fair value in chart for subscribers. The fair value of Windtree Therapeutics, Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Windtree Therapeutics, Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for WINT so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Windtree Therapeutics, Inc. a good stock to buy?

The fair value guage provides a quick view whether WINT is over valued or under valued. Whether Windtree Therapeutics, Inc. is cheap or expensive depends on the assumptions which impact Windtree Therapeutics, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for WINT.

What is Windtree Therapeutics, Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri May 03 2024, WINT's PE ratio (Price to Earnings) is -2.27 and Price to Sales (PS) ratio is 242.57. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. WINT PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Windtree Therapeutics, Inc.'s stock?

In the past 10 years, Windtree Therapeutics, Inc. has provided -0.712 (multiply by 100 for percentage) rate of return.